KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) Revenue (2019 - 2025)

GoodRx Holdings (GDRX) has disclosed Revenue for 7 consecutive years, with $194.8 million as the latest value for Q4 2025.

  • Quarterly Revenue fell 1.91% to $194.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $796.9 million through Dec 2025, up 0.57% year-over-year, with the annual reading at $796.9 million for FY2025, 0.57% up from the prior year.
  • Revenue hit $194.8 million in Q4 2025 for GoodRx Holdings, down from $196.0 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $213.3 million in Q4 2021 to a low of $160.4 million in Q1 2021.
  • Historically, Revenue has averaged $192.6 million across 5 years, with a median of $195.2 million in 2021.
  • Biggest five-year swings in Revenue: surged 43.26% in 2021 and later fell 13.67% in 2022.
  • Year by year, Revenue stood at $213.3 million in 2021, then fell by 13.67% to $184.1 million in 2022, then grew by 6.81% to $196.6 million in 2023, then rose by 0.99% to $198.6 million in 2024, then dropped by 1.91% to $194.8 million in 2025.
  • Business Quant data shows Revenue for GDRX at $194.8 million in Q4 2025, $196.0 million in Q3 2025, and $203.1 million in Q2 2025.